Enanta Pharmaceuticals Inc.
ENTAHeld by 4 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying4 funds opened new positions. Next phase2 readout (zelicapavir): Dec 2026. Short interest: 8.7% of float.
Held by 4 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying4 funds opened new positions. Next phase2 readout (zelicapavir): Dec 2026. Short interest: 8.7% of float.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.